SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT01717404

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Effects of Mexiletine on Colonic Transit in a Patient With a Known SCN5A A997T Mutation

To understand if Mexiletine will restores normal colonic motility in a patient with irritable bowel syndrome - constipation (IBS-C) and a genetic mutation in SCN5A.

NCT01717404 IBS

1 Interventions

Name: Mexiletine

Description: 6-day treatment period during which the medication will be taken orally with an initial dose of: 200 mg every 8 hours for 3 doses on day 3, increasing to 300 mg every 8 hours on days 4 and 5 (6 doses), and increasing further to 400 mg every 8 hours on days 6-8 if no telemetry changes and no dose limiting side effects

Type: Drug

Mexiletine


Primary Outcomes

Description: Colon transit will be measured using validated scintigraphy methods conducted in our Clinical Research Unit (CRU).[17, 18] The participant will ingest a Tc-99m labeled sulfur colloid in egg to be used as a stomach marker and ln-111 chloride bound to activated charcoal enclosed in a methacrylate-coated capsule to measure colonic transit.

Measure: change in the 48 hour Colon Transit

Time: Baseline to 10 days

Purpose: Treatment

Single Group Assignment


There is one SNP

SNPs


1 A997T

Effects of Mexiletine on Colonic Transit in a Patient With a Known SCN5A A997T Mutation. --- A997T ---

18] The participant will ingest a Tc-99m labeled sulfur colloid in egg to be used as a stomach marker and ln-111 chloride bound to activated charcoal enclosed in a methacrylate-coated capsule to measure colonic transit.. Inclusion Criteria: - Established IBS diagnosis with a known A997T mutation in NaV1.5T --- A997T ---

Patient is currently not on any of these medications Inclusion Criteria: - Established IBS diagnosis with a known A997T mutation in NaV1.5T --- A997T ---



HPO Nodes